FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:688-689 March 1, 2001 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Lindahl and colleagues (Oct. 19 issue)¹ report that elevated levels of troponin T and C-reactive protein are predictors of the long-term risk of death from cardiac causes in patients with unstable coronary artery disease. They specify the use of cardiac medications at admission in Table 1 but do not mention any concurrent treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). The statins do more than just lower cholesterol levels.² Recent evidence demonstrates that they appear to be potent and effective cardioprotective agents that inhibit leukocyte–endothelial cell interactions, possibly through enhanced endothelial release of nitric oxide,³ which itself . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wu, J. T., Wu, L. L. (2005). Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis. Annals of Clinical & Laboratory Science 35: 240-250 [Abstract] [Full Text]  
• Aziz, N., Fahey, J. L., Detels, R., Butch, A. W. (2003). Analytical Performance of a Highly Sensitive C-Reactive Protein-Based Immunoassay and the Effects of Laboratory Variables on Levels of Protein in Blood. CVI 10: 652-657 [Abstract] [Full Text]